Abstracts tagged "immunosuppressants"

Abstract Number: 1420 • ACR Convergence 2021
Evaluation of SARS-CoV-2 Vaccine Response in a Multi-Racial/Ethnic Cohort of Patients with Systemic Lupus Erythematosus
Peter Izmirly¹, Mimi Kim², Marie Samanovic-Golden³, Ruth Fernandez Ruiz⁴, Sharon Ohana³, Alexis Engel⁵, Kristina Deonaraine¹, Mala Masson⁴, Xianhong Xie⁶, Amber Cornelius⁴, Ramin Herati⁴, Rebecca Haberman⁴, Jose Scher¹, Allison Guttmann³, Rebecca Blank⁷, Ben Plotz³, Mayce Haj-Ali⁴, Brittany Banbury³, Sara Stream⁸, Ghadeer Hasan³, Gary Ho³, Paula Rackoff⁷, Ashira Blazer³, H. Michael Belmont³, Amit Saxena³, Mark Mulligan⁴, Robert Clancy⁴ and Jill Buyon³, ¹New York University School of Medicine, New York, NY, ²Albert Einstein College of Medicine, Larchmont, NY, ³NYU School of Medicine, New York, NY, ⁴NYU Grossman School of Medicine, New York, NY, ⁵NYU Langone Health, New Yok, NY, ⁶Department of Epidemiology and Public Health, Albert Einstein College of Medicine, Bronx, NY, ⁷New York University, New York, NY, ⁸NYU Langone Health, New York, NY
Background/Purpose: Since the Phase 3 clinical studies of all three COVID-19 vaccines excluded patients on immunosuppressants or immune-modifying drugs within 6 months of enrollment, data…
Abstract Number: 119 • 2020 Pediatric Rheumatology Symposium
Actual Medication Usage of Patients with Juvenile Onset Systemic Lupus Erythematosus Using Japanese Health Insurance Database
Takayuki Kishi¹, Takako Miyamae ², Ryoko Sakai ³, Yumi Tani ², Satoru Nagata ¹ and Masayoshi Harigai ³, ¹Department of Pediatrics, Tokyo Women's Medical University, Tokyo, Japan, ²Pediatric Rheumatology, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ³Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: Background: Immunosuppressive therapy is the mainstay of treatment of child systemic lupus erythematosus (cSLE). However until very recently, the treatment of cSLE lacked uniformity.…
Abstract Number: 2124 • 2019 ACR/ARP Annual Meeting
Screening and Follow-up of Patients with Rheumatic Diseases and Rheumatological Treatments Infected with Trypanosoma Cruzi (American Trypanosomiasis or Chagas’ Disease). Is It Possible a Reactivation?
Ariana Ringer¹, Juan Pablo Ruffino ², Nadia Cuadranti ², Ignacio Rolla ², Juan Manuel Vandale ², Carla Achilli ², Cecilia Argento ², Florencia Martinez ², Noel Cortese ², Mariano Palatnik ², Mariana Lagrutta ³, Rodolfo Leiva ⁴, Damian Aguila ⁵, Maria Jose Svetaz ⁶, Laura Cordoba ⁷, Milagros Zafra ⁸, Telma Gambander ⁸, Patricia Sciarrata ⁶, Silvina Villar ⁹, Florencia Gonzalez ⁹, Florencia Pacini ⁹, Ana Rosa Perez ⁹, Oscar Bottasso ⁹ and Marcelo Abdala ², ¹Rheumatology. Hospital Provincial del Centenario. Universidad Nacional de Rosario, Totoras, Santa Fe, Argentina, ²Rheumatology. Hospital Provincial del Centenario. Universidad Nacional de Rosario, Rosario, ³Internal Medicine. Hospital Provincial del Centenario. Universidad Nacional de Rosario, Rosario, ⁴Cardiology. Hospital Provincial del Centenario. Universidad Nacional de Rosario, Rosario, ⁵Infectology. Hospital Provincial del Centenario. Universidad Nacional de Rosario, Rosario, ⁶Central Laboratory. UNR, Rosario, ⁷Microbiology, Rosario, ⁸Microbiology. UNR, Rosario, ⁹Immunology. IDICER, CONICET, UNR, Rosario
Background/Purpose: American Trypanosomiasis or Chagas Disease (CD) is a zoonotic infection, endemic in Latin America. It is a major cause of morbidity, mortality and economic…
Abstract Number: 2135 • 2019 ACR/ARP Annual Meeting
Therapeutic Strategies and Survival in Patients with Interstitial Pneumonia with Autoimmune Features
Marco Sebastiani¹, Giulia Cassone ², Caterina Vacchi ¹, Lisa De Pasquale ¹, Stefania Cerri ³, Giovanni Della Casa ⁴, Carlo Salvarani ¹ and Andreina Manfredi ¹, ¹Rheumatology Unit, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria Policlinico di Modena, MOdena, Emilia-Romagna, Italy, ²Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Emilia-Romagna, Italy, ³Respiratory Disease Unit, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Emilia-Romagna, Italy, ⁴Radiology Unit, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Emilia-Romagna, Italy
Background/Purpose: Recently the term “interstitial pneumonia with autoimmune features” (IPAF) has been proposed to identify patients with interstitial lung disease and autoimmune characteristics, not fulfilling…
Abstract Number: 2782 • 2019 ACR/ARP Annual Meeting
Comparative Risks of Cardiovascular Disease Among SLE Patients Receiving Immunosuppressive Medications
Daniel Li¹, Candace Feldman ¹, Hongshu Guan ¹, Brendan Everett ², Seoyoung C. Kim ³ and Karen Costenbader ², ¹Brigham and Women's Hospital, Boston, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women’s Hospital and Harvard Medical School, Boston
Background/Purpose: Human studies examining cardiovascular disease (CVD) risk associated with immunosuppressants (IS) have been limited, but mycophenolate mofetil (MMF) was shown to suppress vascular smooth muscle…
Abstract Number: 1198 • 2019 ACR/ARP Annual Meeting
Practice Based Education Program to Increase Vaccination Rate in Patients on Immunotherapeutic Agents
Andrea Soliman¹, Soorya Aggarwal ¹, Kyle Kreitman ¹, Kourtney Erickson ¹, Abdul Aleem ¹ and Marie O'Brien ¹, ¹Lehigh Valley Health Network, Allentown, PA
Background/Purpose: Immunosuppressive agents have changed the course of debilitating autoimmune conditions. Despite their advantages, these agents come with risk of vaccine preventable infections.1 Multiple organizations recommend…
Abstract Number: 343 • 2018 ACR/ARHP Annual Meeting
Low Rates of Immunizations in Cohort of Immunocompromised Patients in an Academic Rheumatology Practice
Dmitriy Cherny¹, Najia Shakoor², Todd Beck³ and Sonali Khandelwal⁴, ¹Internal Medicine, Rush University Medical Center, Chicago, IL, ²Division of Rheumatology, Rush University Medical Center, Chicago, IL, ³Bioinformatics, Rush University Medical Center, Chicago, IL, ⁴Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: Patients with rheumatologic disorders often require immunosuppression (e.g. DMARDs, biologics, or high doses of prednisone). These patients are at increased risk for infections. While…
Abstract Number: 705 • 2018 ACR/ARHP Annual Meeting
Prevalence of Cervical Human Papillomavirus Infection in Women with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
Claudia Mendoza Pinto^1,2, Nicolás Molano-González³, Adriana Rojas-Villarraga⁴, Verónica Vallejo-Ruiz⁵, Socorro Méndez-Martínez⁶ and Mario García-Carrasco^1,7, ¹Systemic Autoimmune Diseases Research Unit,, UMAE, HE CMN Manuel Ávila Camacho-CIBIOR, Instituto Mexicano del Seguro Social, Puebla, Mexico, ²Departament of Research, Facultad de Medicina, Benemerita Universidad Autonoma de Puebla, Puebla, Mexico, ³Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogota, Colombia, ⁴Instituto de Investigaciones de la Fundación Universitaria de Ciencias de la Salud (FUCS), Bogotá, Colombia, ⁵Virology Laboratory, Centro de Investigación Biomédica de Oriente, Instituto Mexicano del Seguro Social, Metepec, Puebla, Mexico, ⁶Research in Health Coordination,, Delegation of Puebla, Instituto Mexicano del Seguro Social, Puebla, Mexico, ⁷Inmunología y Reumatología, Universidad Autónoma de Puebla, Puebla, Mexico
Background/Purpose: Human papillomavirus (HPV), a common sexually-transmitted infection, is considered a necessary cause of cervical cancer. The objectives of this systematic review and meta-regression were:…
Abstract Number: 1234 • 2018 ACR/ARHP Annual Meeting
Incidence of Conversion of Screening Tests for M. Tuberculosis (PPD, GIF-release assay) in a Metropolitan Cohort of Patients Treated with TNF-α Inhibitors
Hung Trinh and Darren Tabechian, Medicine, Division of Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Tumor necrosis factor alpha (TNF-α) inhibitors are used to reduce the inflammatory process in many autoimmune diseases. Due to the risk of reactivation of…
Abstract Number: 1249 • 2018 ACR/ARHP Annual Meeting
Contraception Compliance in Patients with Rheumatological Diseases on Disease Modifying Antirheumatic and Cytotoxic Drugs
Sara Naji Rad¹, Paris Pacheco², Luis Calvo², Htet Htet Maung², Wajiha Illyas² and Prachi Anand³, ¹Internal Medicine, Nassau University Medical Center, East meadow, NY, ²Internal Medicine, Nassau University Medical Center, East Meadow, NY, ³Chief of Rheumatology, Nassau University Medical Center, East Meadow, NY
Background/Purpose: Women of child bearing age with autoimmune diseases are often prescribed teratogenic medications as Methotrexate, Mycophenolate Mofetil, Leflunomide and Cyclophosphamide. Contraceptive compliance in this…
Abstract Number: 1289 • 2018 ACR/ARHP Annual Meeting
Immunosuppressant Use and Gout in the Prevalent Solid Organ Transplant Population
Andrew Milgroom¹, Mara Onita Lenco¹, Kevin Francis¹, Jeffrey D. Kent², Brian LaMoreaux³ and Brian F. Mandell⁴, ¹Trinity Partners, Waltham, MA, ²Medical Affairs, Horizon Pharma USA, Inc, Lake Forest, IL, ³Horizon Pharma USA, Inc, Lake Forest, IL, ⁴Rheumatology, Cleveland Clinic, Cleveland, OH
Background/Purpose: Gout is a frequent co-morbidity of solid organ transplant (SOT). Cyclosporine (CsA) is often cited as the main cause of gout in SOT, as…
Abstract Number: 1768 • 2018 ACR/ARHP Annual Meeting
Kidney Involvement, Poor Performance Status, and Higher Cumulative Dose of Glucocorticoid Are the Risk Factors of the Discontinuation of Immunosuppressant in Patients with Antineutrophil Cytoplasmic Antibody Associated Vasculitis
Takamasa Murosaki, Takeo Sato, Katsuya Nagatani and Seiji Minota, Department of Internal Medicine, Division of Rheumatology/Clinical Immunology, Jichi Medical University, Shimotsuke, Japan
Background/Purpose: The use of immunosuppressant (IS) with glucocorticoid is recommended as remission induction treatment for severe cases with antineutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV).…
Abstract Number: 1877 • 2018 ACR/ARHP Annual Meeting
Specific Pneumoproteins Predict Progression of Interstitial Lung Disease in Systemic Sclerosis Patients Undergoing Treatment with Immunosuppression
Elizabeth R. Volkmann¹, Donald P. Tashkin¹, Masataka Kuwana², Ning Li³, Julio Charles⁴, Faye N. Hant⁵, Galina S. Bogatkevich⁶, Tanjina Akter⁶, Michael Roth⁷, Hyun J. Grace Kim⁸, Jonathan Goldin⁹, Dinesh Khanna¹⁰, Philip J. Clements¹¹, Daniel E. Furst⁷, Robert Elashoff¹², Rick Silver¹³ and Shervin Assassi¹⁴, ¹University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ³Biomathematics, University of California, Los Angeles, Los Angeles, CA, ⁴University of Texas Health Science Center at Houston, Houston, TX, ⁵Rheumatology, Medical University of South Carolina, Charleston, SC, ⁶Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, SC, ⁷Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁸Department of Radiology, David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁹Department of Radiological Sciences at UCLA, University of California, Los Angeles, David Geffen School of Medicine, Santa Monica, CA, ¹⁰Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, ¹¹Medicine, University of California, Los Angeles, Los Angeles, CA, ¹²University of California, Los Angeles, Los Angeles, CA, ¹³Rheumatology, Medical University of SC, Charleston, SC, ¹⁴University of Texas McGovern Medical School, Houston, TX
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of death in systemic sclerosis (SSc). While some SSc-ILD patients are stable or improve with immunosuppressive…
Abstract Number: 1878 • 2018 ACR/ARHP Annual Meeting
Immunosuppression in Diffuse Systemic Sclerosis Improves Outcomes Using a Novel Composite Response Index
Boyang Zheng¹, Mianbo Wang² and Murray Baron³, ¹Rheumatology, McGill University Health Center (MUHC), Montreal, QC, Canada, ²Lady Davis Institute for Medical Research, Montreal, QC, Canada, ³Rheumatology, McGill University, Jewish General Hospital, Montreal, QC, Canada
Background/Purpose: Diffuse systemic sclerosis (dcSSc) is a devastating multi-organ disease where the mainstay of treatment is immunosuppression. Data on these therapies are mostly based on…
Abstract Number: 2269 • 2018 ACR/ARHP Annual Meeting
Infliximab Therapy in Refractory Retinal Vasculitis of Behçet’s Disease, Short and Long-Term Follow-up. Multicenter Study of 72 Patients
José Luis Martín-Varillas¹, Belén Atienza-Mateo¹, Vanesa Calvo-Río², Diana Prieto Peña², Monica Calderón Goercke², Rosalía Demetrio-Pablo³, Javier Loricera³, M. Victoria Hernández⁴, Alfredo Adan⁵, Marina Mesquida⁵, Diana Peiteado⁶, David Diaz-Valle⁷, Lucía Martínez-Costa⁸, Elia Valls-Pascual⁸, Miguel A. Caracuel⁹, Angel Garcia-Aparicio¹⁰, Jose M Herreras¹¹, Miguel Cordero-Coma¹², Carlos Alberto Montilla-Morales¹³, Alejandro Fonollosa¹⁴, Antonio Atanes¹⁵, Félix Francisco¹⁶, Ignacio Torre-Salaberri¹⁷, Olga Maíz¹⁸, Ana Blanco¹⁹, Cruz Fernandez-Espartero²⁰, Norberto Ortego Centeno²¹, Enrique Raya Álvarez²², Myriam Gandía²³, Francisco Javier López Longo²⁴, Maria Alcalde-Villar²⁵, Cristina Fernández-Carballido²⁶, Esperanza Pato Cour²⁷, Oscar Ruiz Moreno²⁸, Fernando Jiménez-Zorzo²⁹, Raquel Almodóvar González³⁰, Carmen Carrasco-Cubero³¹, Luis Francisco Linares³², Fredeswinda I. Romero-Bueno³³, Santos Insua³⁴, Senen González-Suárez³⁵, Marisa Hernández³⁶, Emma Beltrán³⁷, Juan Cruz³⁸, Carlos Férnandez Cid³⁹, Elena Aurrecoechea⁴⁰, Enar Pons¹, Miguel Angel González-Gay³ and Ricardo Blanco¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²Rheumatology, Rheumatology. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ³Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ⁴Rheumatology, Hospital Clinic. Barcelona. Spain, Barcelona, Spain, ⁵Hospital Clinic. Barcelona. Spain, Barcelona, Spain, ⁶Rheumatology, Rheumatology, La Paz University Hospital, Madrid, Spain, ⁷Hospital Clínico San Carlos. Madrid. Spain, Madrid, Spain, ⁸Hospital Universitario Doctor Peset. Valencia. Spain, Valencia, Spain, ⁹Hospital de Córdoba, Córdoba, Spain., Córdoba, Spain, ¹⁰Rheumatology, Hospital de Toledo. Toledo. Spain, Toledo, Spain, ¹¹Ophthalmology, Hospital Universitario, IOBA. Valladolid. Spain, Valladolid, Spain, ¹²Ophthalmology, Hospital de León. Spain, León, Spain, ¹³Hospital Clínico Universitario de Salamanca. Spain, Salamanca, Spain, ¹⁴Ophthalmology, Hospital de Cruces. Bilbao. Spain, Bilbao, Spain, ¹⁵Complejo Hospitalario Universitario A Coruña. Spain, A Coruna, Spain, ¹⁶Rheumatology, Hospital Doctor Negrín. Las Palmas de Gran Canaria. Spain, Las Palmas de Gran Canaria, Spain, ¹⁷Rheumatology, Hospital Universitario de Basurto. Bilbao. Spain, Bilbao, Spain, ¹⁸Hospital Universitario Donostia. San Sebastian. Spain, San Sebastián, Spain, ¹⁹Ophtamology, Hospital Universitario Donostia. San Sebastian. Spain, San Sebastian, Spain, ²⁰Rheumatology, Hospital de Móstoles. Madrid. Spain, Madrid, Spain, ²¹Medicine Department, Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, ²²Rheumatology, Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, ²³Rheumatology, Hospital Puerta del Mar. Cádiz. Spain, Cádiz, Spain, ²⁴Rheumatology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²⁵Hospital Severo Ochoa, Madrid, Spain, Madrid, Spain, ²⁶Rheumatology Division, Hospital General Universitario de Elda, Elda, Spain, ²⁷Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ²⁸Ophthalmology and Rheumatology, Hospital Miguel Servet. Zaragoza. Spain, Zaragoza, Spain, ²⁹Hospital Miguel Servet. Zaragoza. Spain, Zaragoza, Spain, ³⁰Rheumatology, Hospital Universitario Fundación Alcorcón. Madrid. Spain, Madrid, Spain, ³¹Hospital de Mérida. Spain, Mérida, Spain, ³²Rheumatology, Hospital Virgen de la Arrixaca. Murcia. Spain, Murcia, Spain, ³³Section for Autoimmune Diseases, Rheumatology, Fundación Jiménez Díaz University Hospital & Health Research Institute, Madrid, Spain, ³⁴Rheumatology, Hospital Universitario Santiago de Compostela. La Coruña. Spain, La Coruña, Spain, ³⁵Rheumatology, Hospital de Cabueñes. Gijón. Spain, Gijón, Spain, ³⁶Ophthalmology, Hospital General Universitario de Valencia. Spain, Valencia, Spain, ³⁷Rheumatology, Hospital del Mar. Barcelona. Spain, Barcelona, Spain, ³⁸Hospital de Pontevedra. Pontevedra. Spain, Pontevedra, Spain, ³⁹Ophthalmology, Hospital de Pontevedra. Pontevedra. Spain, Pontevedra, Spain, ⁴⁰Rheumatology, Hospital de Sierrallana, Torrelavega. Cantabria. Spain, Torrelavega, Spain
Background/Purpose: Retinal vasculitis is a serious complication of uveitis due to Behçet’s disease (BD). The treatment is based on corticosteroids, conventional immunosuppressants (IS) and anti-TNF-α…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].